| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 187 | 1.890 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2021 | 28 | 1.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2019 | 30 | 1.170 |
Why?
|
| Antibodies, Monoclonal | 8 | 2011 | 150 | 0.960 |
Why?
|
| Arabinonucleosides | 4 | 2021 | 6 | 0.950 |
Why?
|
| Lymphoma | 3 | 2023 | 31 | 0.940 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2019 | 26 | 0.940 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2023 | 9 | 0.920 |
Why?
|
| Rituximab | 16 | 2023 | 40 | 0.910 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 155 | 0.800 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 11 | 2017 | 26 | 0.740 |
Why?
|
| Adenine Nucleotides | 2 | 2010 | 3 | 0.670 |
Why?
|
| Burkitt Lymphoma | 3 | 2021 | 7 | 0.550 |
Why?
|
| Paraproteinemias | 2 | 2019 | 4 | 0.530 |
Why?
|
| Middle Aged | 25 | 2023 | 7555 | 0.490 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2015 | 6 | 0.480 |
Why?
|
| Humans | 43 | 2023 | 22848 | 0.470 |
Why?
|
| Adult | 21 | 2021 | 6584 | 0.470 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 48 | 0.460 |
Why?
|
| Treatment Outcome | 18 | 2021 | 2960 | 0.450 |
Why?
|
| Aged | 22 | 2023 | 7669 | 0.440 |
Why?
|
| Male | 25 | 2022 | 12453 | 0.420 |
Why?
|
| Cyclophosphamide | 9 | 2021 | 37 | 0.380 |
Why?
|
| Necrobiotic Xanthogranuloma | 1 | 2011 | 1 | 0.370 |
Why?
|
| Plasma Cells | 1 | 2011 | 5 | 0.370 |
Why?
|
| Mediastinum | 1 | 2011 | 5 | 0.370 |
Why?
|
| Female | 26 | 2021 | 12677 | 0.370 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 3 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 13 | 0.350 |
Why?
|
| Doxorubicin | 7 | 2021 | 32 | 0.350 |
Why?
|
| Aged, 80 and over | 11 | 2023 | 4055 | 0.350 |
Why?
|
| Arsenicals | 2 | 2007 | 11 | 0.330 |
Why?
|
| Oxides | 2 | 2007 | 15 | 0.330 |
Why?
|
| Cranial Irradiation | 2 | 2007 | 5 | 0.330 |
Why?
|
| Vincristine | 7 | 2019 | 20 | 0.320 |
Why?
|
| Prednisone | 7 | 2019 | 61 | 0.310 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 9 | 0.300 |
Why?
|
| Cachexia | 2 | 2019 | 9 | 0.290 |
Why?
|
| Disease-Free Survival | 7 | 2021 | 138 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 125 | 0.290 |
Why?
|
| HIV Infections | 2 | 2021 | 369 | 0.280 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2007 | 1 | 0.270 |
Why?
|
| Sarcoma, Myeloid | 1 | 2007 | 4 | 0.270 |
Why?
|
| Ear Neoplasms | 1 | 2007 | 8 | 0.270 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2023 | 15 | 0.270 |
Why?
|
| Recurrence | 6 | 2020 | 262 | 0.260 |
Why?
|
| Brain Neoplasms | 2 | 2006 | 69 | 0.260 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 11 | 0.260 |
Why?
|
| Drug Administration Schedule | 6 | 2019 | 119 | 0.250 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2006 | 10 | 0.250 |
Why?
|
| Biomarkers | 3 | 2019 | 453 | 0.250 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 214 | 0.240 |
Why?
|
| Prognosis | 6 | 2021 | 630 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2008 | 49 | 0.230 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2003 | 2 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 3 | 2008 | 7 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 14 | 0.200 |
Why?
|
| Remission Induction | 6 | 2015 | 70 | 0.190 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2011 | 18 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 52 | 0.180 |
Why?
|
| Thrombosis | 1 | 2021 | 38 | 0.180 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3062 | 0.170 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2020 | 1 | 0.170 |
Why?
|
| Benzylidene Compounds | 1 | 2020 | 1 | 0.170 |
Why?
|
| Azepines | 1 | 2020 | 3 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 17 | 0.170 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 17 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 29 | 0.160 |
Why?
|
| Young Adult | 4 | 2021 | 1721 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 7 | 0.160 |
Why?
|
| Central Nervous System | 3 | 2023 | 40 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 270 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 7 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 46 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 16 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 64 | 0.150 |
Why?
|
| Neutropenia | 4 | 2012 | 12 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2019 | 66 | 0.150 |
Why?
|
| Cytosine | 2 | 2021 | 3 | 0.150 |
Why?
|
| Cardiology | 1 | 2018 | 23 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 175 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2018 | 31 | 0.150 |
Why?
|
| Immunity | 1 | 2017 | 13 | 0.130 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 5 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 43 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2016 | 27 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2019 | 157 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 166 | 0.120 |
Why?
|
| Biopsy | 2 | 2019 | 181 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 13 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 45 | 0.110 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2004 | 26 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 7 | 0.110 |
Why?
|
| Leukopenia | 2 | 2011 | 6 | 0.110 |
Why?
|
| Lymphoma, Follicular | 2 | 2011 | 4 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2004 | 143 | 0.100 |
Why?
|
| Methotrexate | 2 | 2023 | 34 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 135 | 0.100 |
Why?
|
| Cytarabine | 3 | 2023 | 9 | 0.100 |
Why?
|
| Daunorubicin | 2 | 2015 | 4 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 227 | 0.100 |
Why?
|
| Transcriptome | 1 | 2012 | 72 | 0.100 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2012 | 2 | 0.100 |
Why?
|
| Obesity | 1 | 2014 | 263 | 0.090 |
Why?
|
| Cytokines | 1 | 2012 | 167 | 0.090 |
Why?
|
| Agranulocytosis | 1 | 2011 | 4 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 5 | 0.090 |
Why?
|
| Yttrium Radioisotopes | 1 | 2011 | 7 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2008 | 45 | 0.090 |
Why?
|
| Retreatment | 1 | 2010 | 4 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2010 | 28 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2011 | 334 | 0.080 |
Why?
|
| Platelet Count | 2 | 2007 | 13 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 588 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2020 | 47 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 685 | 0.070 |
Why?
|
| Tretinoin | 1 | 2007 | 13 | 0.070 |
Why?
|
| Weight Loss | 2 | 2019 | 107 | 0.070 |
Why?
|
| Injections, Spinal | 1 | 2007 | 31 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1494 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2006 | 2 | 0.060 |
Why?
|
| ADAMTS13 Protein | 1 | 2006 | 5 | 0.060 |
Why?
|
| Plasma Exchange | 1 | 2006 | 12 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2006 | 31 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2006 | 38 | 0.060 |
Why?
|
| United States | 2 | 2021 | 1726 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 99 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2006 | 61 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 89 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2019 | 210 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 549 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2021 | 1621 | 0.060 |
Why?
|
| Twins, Dizygotic | 1 | 2005 | 3 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 4 | 0.060 |
Why?
|
| Thalidomide | 1 | 2004 | 7 | 0.060 |
Why?
|
| Etoposide | 2 | 2019 | 23 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 1 | 0.060 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 4 | 0.050 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2003 | 4 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 29 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2003 | 16 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2003 | 4 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 15 | 0.050 |
Why?
|
| K562 Cells | 1 | 2003 | 3 | 0.050 |
Why?
|
| Telomerase | 1 | 2003 | 9 | 0.050 |
Why?
|
| Histones | 1 | 2003 | 25 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 118 | 0.050 |
Why?
|
| Apoptosis | 1 | 2003 | 172 | 0.050 |
Why?
|
| Risk Factors | 2 | 2005 | 1942 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 1 | 0.050 |
Why?
|
| Voriconazole | 1 | 2022 | 10 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2022 | 34 | 0.050 |
Why?
|
| Azacitidine | 1 | 2021 | 8 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 42 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2021 | 4 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 8 | 0.040 |
Why?
|
| Incidence | 1 | 2023 | 649 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2006 | 819 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 17 | 0.040 |
Why?
|
| Anemia | 2 | 2012 | 30 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 470 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 20 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 539 | 0.040 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 2 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 12 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 12 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 1 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 3 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 12 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 16 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 238 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 947 | 0.040 |
Why?
|
| Vidarabine | 2 | 2011 | 4 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 26 | 0.040 |
Why?
|
| Body Composition | 1 | 2019 | 52 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 16 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 71 | 0.040 |
Why?
|
| Cardiologists | 1 | 2018 | 6 | 0.040 |
Why?
|
| Mitoxantrone | 2 | 2011 | 4 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 82 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 381 | 0.040 |
Why?
|
| Bortezomib | 1 | 2017 | 3 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2015 | 1528 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 554 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 205 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 2 | 2006 | 7 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 162 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 1775 | 0.030 |
Why?
|
| Naphthalimides | 1 | 2015 | 1 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 1 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 2 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 401 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 32 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 40 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 107 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 6 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2014 | 354 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2003 | 254 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 82 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 63 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1220 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 45 | 0.020 |
Why?
|
| Animals | 1 | 2014 | 3025 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 21 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 33 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2007 | 19 | 0.020 |
Why?
|
| Cisplatin | 1 | 2007 | 50 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 259 | 0.020 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 3 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 10 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 22 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 23 | 0.010 |
Why?
|
| Teniposide | 1 | 2004 | 1 | 0.010 |
Why?
|
| Bleomycin | 1 | 2004 | 2 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 157 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 307 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2004 | 21 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 127 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 126 | 0.010 |
Why?
|
| S Phase | 1 | 2003 | 9 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2003 | 5 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2003 | 5 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 10 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 9 | 0.010 |
Why?
|
| Granulocytes | 1 | 2003 | 11 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 44 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 32 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 49 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 75 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 130 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 92 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 109 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 147 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2003 | 67 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 305 | 0.010 |
Why?
|